Niels Riedemann

Company: Inflarx N. V.

Job title: CEO

Seminars:

The Life-Saving Anti-Inflammatory Potential of Blocking the C5a / C5aR Signaling Pathway 5:10 pm

Controlling the C5a/C5aR signaling pathway: what does it take? The first-in-class monoclonal anti-C5a antibody vilobelimab (Gohibic): US EUA in critical COVID-19 space and development beyond INF904: a new oral chemical inhibitor of C5aR with best in class potentialRead more

day: Conference Day One

Panel Discussion: What are the Future Applications of Complement Therapeutics; What Will the Landscape Look Like in 5 Years’ Time? 4:00 pm

Reflecting on all the incredible insights shared today and our key takings, where do we see the complement landscape going? With an increasing appreciation of complement’s role in other conditions, do we see commercial opportunity in tackling neurological diseases? Will emerging modalities and tissue specific therapies reduce safety and toxicity effects of immunosuppressants? With regulatory…Read more

day: Conference Day Two